News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Subscribe To Our Newsletter & Stay Updated
